First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer
NCT01437618
·
clinicaltrials.gov ↗
COMPLETED
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Colorectal Cancer
Interventions
DRUG:
FOLFOXIRI plus bevacizumab
Sponsor
Azienda Ospedaliero, Universitaria Pisana